GLUEMonte Rosa Therapeutics, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 16076
Ticker: GLUE
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2021-06-24
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: GLUE

Detail

Enriched 2026-08-14 20:47

Market cap: $1,360,748,745.95
Shares outstanding (class): 85,313,401
Shares outstanding (weighted): 85,313,401
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 173
Location: BOSTON, MA
Homepage: https://www.monterosatx.com
Description: Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

Market cap and share counts drift.

Funds holding this security

115 funds · 117 positions · $247.10M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$38.50M	0.00%	2,340,527 NS	FIGI
T. Rowe Price New Horizons Fund, Inc. T. ROWE PRICE NEW HORIZONS FUND, INC.	—	$32.68M	0.26%	1,986,382 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$32.35M	0.44%	1,966,731 NS	FIGI
T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC.	—	$30.75M	0.28%	1,869,110 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$24.23M	0.03%	1,472,878 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$11.31M	0.01%	687,537 NS	FIGI
T. Rowe Price Integrated U.S. Small-Cap Growth … T. ROWE PRICE INTEGRATED EQUITY FUNDS, INC.	—	$9.30M	0.11%	565,639 NS	FIGI
iShares Russell 2000 Value ETF iShares Trust	IWN	$8.52M	0.07%	518,037 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$5.70M	0.07%	346,430 NS	FIGI
Small Cap Value Fund Northern Funds	—	$4.47M	0.72%	271,646 NS	FIGI
Allspring Opportunity Fund ALLSPRING FUNDS TRUST	—	$3.41M	0.20%	207,241 NS	FIGI
Nomura Healthcare Fund Delaware Group Equity Funds IV	—	$3.29M	0.49%	200,000 NS	FIGI
Omni Small-Cap Value Fund Bridgeway Funds, Inc.	—	$3.13M	0.26%	190,000 NS	FIGI
iShares Micro-Cap ETF iShares Trust	IWC	$2.51M	0.21%	152,674 NS	FIGI
VictoryShares US Small Mid Cap Value Momentum E… Victory Portfolios II	USVM	$2.05M	0.14%	124,636 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERGLUE
FIGI_COMPOSITEBBG00X2VGZQ3
FIGI_SHARE_CLASSBBG00X2VGZR2
CIK0001826457
ISINUS61225M1027
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Monte Rosa Therapeutics is a biopharmaceutical company focused on developing molecular glue degraders, fitting the biotechnology industry.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.